Sulfobutylether-β-cyclodextrin (SBE-β-CD) is a commonly used pharmaceutical excipient widely employed to enhance the solubility and bioavailability of poorly soluble drugs. In the process of drug development and formulation, the safety of excipients is crucial as they directly impact the quality of the final drug formulation and the safety of patients.
Several studies have been conducted to evaluate the toxicity of SBE-β-CD and its potential impact on humans. Experimental results indicate that at recommended doses, SBE-β-CD does not exhibit significant acute or subchronic toxicity in the body, and long-term exposure does not show any apparent carcinogenic or mutagenic effects.
Studies suggest that SBE-β-CD undergoes stable metabolism in the body, and its metabolites are non-toxic to humans. Its interactions with biological systems and excretion pathways have been widely studied, showing good biocompatibility.
Extensive clinical research and practical pharmaceutical applications have confirmed the safety of SBE-β-CD in formulations. Many commonly used pharmaceutical formulations utilize SBE-β-CD as an excipient, with clinical trials demonstrating its safety and tolerability in humans.
Scientific and rational use of SBE-β-CD in drug development and formulation processes will help ensure the safety and efficacy of pharmaceutical formulations, enhancing the treatment experience for patients.
